Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

ImpediMed Takes Aim At $1.5B Market With US Launch Of L-Dex For Assessing Lymphedema In Cancer Survivors

Executive Summary

In January, ImpediMed began a national launch of L-Dex, a bioimpedance spectroscopy device designed to allow early detection and treatment of secondary lymphedema, a condition caused by cancer treatment that affects about 900,000 US patients each year – a market estimated at $1.5 billion. Early detection and treatment can greatly reduce or even reverse progression of the disease, and the company is also investigating potential applications in heart failure, a much larger market.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register